OmniAb, Inc. Warrant (OABIW) Stock Price
OABIWStock
$0.24
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta1.89
OABIW Share Price Chart
Favorite Metrics
Price vs S&P 500 (4W)12.57%
VGM Score67.48
Industry Peers — R&D — Physical Sciences(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
OABIWOmniAb, Inc. Warrant | — | — | B | — | — | — | — | $0.24 |
| IQVIQVIA Holdings Inc. | D | C | A | 32.3x | 21.9% | 7.5% | — | $266.90 |
| INCYIncyte Genomics Inc | C | B | B | 17.8x | 29.6% | 14.0% | — | $113.07 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | 38.3x | 110.2% | 22.3% | — | $618.47 |
| CRLCharles River Laboratories International, Inc. | F | D | A | — | -7.7% | 6.5% | — | $300.15 |
| ICLRIcon Plc | C | C | B | 57.3x | 0.8% | 24.1% | — | $170.18 |
| ABSIAbsci Corporation Common Stock | F | F | B | — | -59.2% | -10.1% | — | $8.25 |
| OABIOmniAb, Inc. Common Stock | F | B | A | — | -16.6% | -4.3% | — | $4.59 |
| NRCNRC Health Common Stock | D | D | B | 38.4x | 48.5% | 0.6% | 1.2% | $20.15 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | — | -21.0% | 4.8% | — | $1.30 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | 15.9x | -3.7% | — | — | $10.86 |
About OmniAb, Inc. Warrant
OmniAb Inc develops proprietary antibody discovery technologies utilizing genetically engineered transgenic animals—OmniRat, OmniMouse, and OmniChicken—that produce fully human therapeutic antibodies optimized through in vivo affinity maturation. The company's platform enables rapid and efficient discovery of high-quality antibodies across diverse disease indications. By reducing development timelines while enhancing therapeutic quality, OmniAb accelerates the path from discovery to clinical application.